Hansa Biopharma AB (CHIX:HNSAS) Beginning Cash Position: kr676.5 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:HNSAS Hansa Biopharma AB CHIX:HNSAS
43 GF Score
Price kr25.64
GF Value kr14.50
! 7 Warning Signs
View Full Analysis

What is Hansa Biopharma AB Beginning Cash Position?

Hansa Biopharma AB CHIX:HNSAS 43 Beginning Cash Position is kr676.5 Mil as of Jun. 2026. GuruFocus rates CHIX:HNSAS with a GF Score™ of 43/100 and a GF Value™ of kr14.50. The stock has 7 warning signs investors should review.

Hansa Biopharma AB's Beginning Cash Position for the quarter that ended in Jun. 2026 was kr676.5 Mil.

Hansa Biopharma AB's quarterly Beginning Cash Position increased from Dec. 2025 (kr252.1 Mil) to Mar. 2026 (kr701.1 Mil) but then declined from Mar. 2026 (kr701.1 Mil) to Jun. 2026 (kr676.5 Mil).

Hansa Biopharma AB's annual Beginning Cash Position declined from Dec. 2023 (kr1,496.2 Mil) to Dec. 2024 (kr732.1 Mil) and declined from Dec. 2024 (kr732.1 Mil) to Dec. 2025 (kr405.3 Mil).

Hansa Biopharma AB Beginning Cash Position Related Terms

Hansa Biopharma AB Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Hansa Biopharma AB's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hansa Biopharma AB Beginning Cash Position Chart

Hansa Biopharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,139.36 651.34 1,496.18 732.06 405.28

Hansa Biopharma AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 250.20 353.32 252.07 701.08 676.46
CHIX:HNSAS
43GF Score
Hansa Biopharma AB CHIX:HNSAS
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hansa Biopharma AB Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of kr676.5 Mil mean?
Hansa Biopharma AB (CHIX:HNSAS) has a Beginning Cash Position of kr676.5 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Hansa Biopharma AB and its competitors.
Is Hansa Biopharma AB's Beginning Cash Position too high?
Hansa Biopharma AB's current Beginning Cash Position is kr676.5 Mil. Overall, Hansa Biopharma AB has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's Beginning Cash Position compare to VRTX and REGN?
Hansa Biopharma AB's Beginning Cash Position of kr676.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Hansa Biopharma AB and its competitors. Hansa Biopharma AB's current Beginning Cash Position is kr676.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Hansa Biopharma AB (CHIX:HNSAS) has a current Beginning Cash Position of kr676.5 Mil. The stock's GF Value™ is kr14.50, compared to a current price of kr25.64 — trading 76.8% above its estimated fair value. The current Beginning Cash Position is kr676.5 Mil. Hansa Biopharma AB's overall GF Score™ is 43/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Hansa Biopharma AB (CHIX:HNSAS), the current Beginning Cash Position is kr676.5 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hansa Biopharma AB (CHIX:HNSAS) Overvalued in 2026?

Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued. The current stock price of kr25.64 is trading 76.8% above its estimated GF Value™ of kr14.50.

Key valuation signals for CHIX:HNSAS:

  • Beginning Cash Position: kr676.5 Mil
  • GF Value™: kr14.50 vs. price of kr25.64 (76.8% above fair value)
  • GF Score™: 43/100 with 7 warning signs

No single metric tells the full story. See the CHIX:HNSAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hansa Biopharma AB Business Description

Address Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
43GF Score

Get the complete analysis for CHIX:HNSAS

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr25.64
Price
kr14.50
GF Value